



CIT

COPY OF PAPERS
ORIGINALLY FILED

1644
D#3

CERTIFICATION OF MAILING

I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: May 21, 2002.

Eva Cavalli
(Print Name)
Eva Cavalli
(Signature)

RECEIVED
JUN 10 2002
TECH CENTER 1600/2907

In Re: Patent Application

Attorney Docket No: P-4296P1C1

Applicant(s): Kenneth A. Davis

Serial No.: 10/080,868

Group Art Unit: to be assigned

Filing Date: Feb. 22, 2002

Examiner: to be assigned

For: **Improved Methods and Reagents for Quantitation of HLA-DR and CD11b Expression on Peripheral Blood Cells**

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington DC 20231,

Sir:

Applicant submit the accompanying Form PTO-1449 pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98. Applicant request that the documents cited on the accompanying Form PTO-1449 be made of record in the above identified application.


With the exception of U.S. Patent No. 6,133,429, a copy of which is submitted herewith, all references cited in the accompanying Form PTO-1449 were made of record in the parent application, Serial No. 09/406,013, from which priority is claimed under 35 U.S.C. § 120, and are not submitted herewith, pursuant to 37 C.F.R. § 1.98(d).

As this Information Disclosure Statement is submitted within three months of the filing date of the application, no fee is due.

The filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56. Applicant reserves the right to challenge the applicability as prior art of any of the above-cited references.

Respectfully submitted,

5/21/02
Date



Douglas A. Petry, Ph.D.

Reg. Nr. 35,321

Agent for Applicant

Tel: (408) 518-5074


Fax: (408) 954-4122

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT JUN 04 2002	ATTY. DOCKET NO. P-4296P1C1	SERIAL NO. 10/080,868
	APPLICANT Kenneth A. Davis	
	FILING DATE February 22, 2002	GROUP

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,932,428	08/1999	Dubrow et al.	435	7.24	
	5,912,134	06/1999	Shartle	435	7.24	
	5,714,386	02/1998	Roederer	436	546	
	5,648,225	07/1997	Kim et al.	435	7.24	
	5,620,842	04/1997	Davis et al.	435	4	
	5,556,764	09/1996	Sizto et al.	435	7.24	
	5,547,849	08/1996	Baer et al.	435	7.24	
	5,516,695	05/1996	Kim et al.	436	17	
	5,510,267	04/1996	Marshall	436	63	
	5,268,486	12/1993	Waggoner et al.	548	427	
	4,902,613	02/1990	Chang et al.	435	2	
	4,876,190	10/1989	Recktenwald	435	7	
	4,654,312	03/1987	Chang et al.	436	519	
	4,405,711	09/1983	Masuda et al.	435	4	
	4,404,289	09/1983	Masuda et al.	436	538	
	4,337,063	06/1982	Mihara et al.	23	230B	
	6,133,429	10/2000	Davis et al.	530	391.5	
	5,426,028	06/1995	Levy et al.	435	7.24	

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT COPY OF PAPERS ORIGINALLY FILED		ATTY. DOCKET NO. P-4296P1C1	SERIAL NO. 10/080,868
		APPLICANT Kenneth A. Davis	
		FILING DATE February 22, 2002	GROUP

FOREIGN PATENT DOCUMENTS						TRANSLATION	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	EP 0747700 A2	12/1996	Europe	G01N	33/533		
	EP 0161770 B1	11/1991	Europe	G01N	33/50		
	WO 98/48017	10/1998	WIPO	C12N	15/12		
	WO 98/35980	08/1998	WIPO	C07H	21/02		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Adorini, L. et al., "Competition for Antigen Presentation in Living Cells Involves Exchange of Peptides Bound by Class II MHC Molecules," <u>Nature</u> , 342(6251):800-803 (1989).
	Asadullah, K. et al., "Immunodepression Following Neurosurgical Procedures," <u>Crit. Care Med.</u> , 23(12):1976-1983 (1995).
	Becton Dickinson Immunocytometry Systems, "QuantiBRITE, Brilliance You Can Measure," 1-4 (1997).
	Bone, R.C., "Sir Issac Newton, Sepsis, SIRS, and CARS," <u>Crit. Care Med.</u> , 24(7):1125-1128 (1996).
	Bone, R.C., "Why Sepsis Trials Fail," <u>JAMA</u> , 276(7):565-566 (1996).
	Cresswell, P., "Assembly, Transport, and Function of MHC Class II Molecules," <u>Annu. Rev. Immunol.</u> , 12:259-293 (1994).
	Davis, K.A., "QuantiBRITE, A New Standard for Fluorescence Quantitation," Becton Dickinson Immunocytometry Systems, 1-15 (1997).
	Deka, C. et al., "Analysis of Fluorescence Lifetime and Quenching of FITC-Conjugated Antibodies on Cells by Phase-Sensitive Flow Cytometry," <u>Cytometry</u> , 25(3):271-279 (1996).
	Döcke, W.-D. et al., "Monocyte Deactivation in Septic Patients: Restoration by IFN- γ Treatment," <u>Nature Medicine</u> , 3(6):678-681 (1997).

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT COPY OF PAPERS ORIGINALLY FILED	ATTY. DOCKET NO. P-4296P1C1	SERIAL NO. 10/080,868
	APPLICANT Kenneth A. Davis	
	FILING DATE February 22, 2002	GROUP RECEIVED




JUN 10 2002

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Döcke, W.-D. et al., "Monitoring der Monozytären HLA-DR-Antigen-Expression bei Transplantation und Sepsis," <u>Durchflusszytometrie in der Klinischen Zelldiagnostik</u> , G. Schmitz et al., eds., 163-177, Stuttgart (1994).
	Döcke, W.-D. et al., "Improvement of Monocyte Function-A New Therapeutic Approach?" in Reinhart et al. (eds.), <u>Sepsis: Current Perspectives in Pathophysiology and Therapy</u> , New York: Springer-Verlag (1994), pp 473-500.
	Ernst, L.A. et al., "Cyanine Dye Labeling Reagents for Sulfhydryl Groups," <u>Cytometry</u> , 10(1): 3-10 (1989).
	Fisher, C.J. et al., "Influence of an Anti-Tumor Necrosis Factor Monoclonal Antibody on Cytokine Levels in Patients with Sepsis," <u>Crit.Care Med.</u> , 21(3):318-327 (1993).
	Fisher, C.J. et al., "Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients with Sepsis Syndrome," <u>JAMA</u> , 271(23):1836-1843 (1994).
	Fisher, C.J. et al., "Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein," <u>N. Engl. J. Med.</u> , 334(26):1697-1702 (1996).
	Hedin, U. et al., "Receptor-Mediated Endocytosis of Immunoglobulin-Coated Colloidal Gold Particles in Cultured Mouse Peritoneal Macrophages. Chloroquine and Monensin Inhibit Transfer of the Ligand from Endocytic Vesicles to Lysosomes," <u>Eur. J. Cell Biol.</u> , 39(1):130-135 (1985).
	Hershman, M.J. et al., "Interferon-Gamma Treatment Increases HLA-DR Expression on Monocytes in Severely Injured Patients," <u>Clin. Exp. Immunol.</u> , 77(1):67-70 (1989).
	Kahan, M., "Detecting Intracellular Cytokines in Activated Monocytes," Application Note 2, Immune Function, Becton Dickinson Immunocytometry Systems, 1-12 (1997).
	Kox, W.J. et al., "Interferon Gamma-1b in the Treatment of Compensatory Anti-Inflammatory Response Syndrome," <u>Arch. Intern. Med.</u> , 157(4):389-393 (1997).
	Lansdorp, P.M. et al., "Single Laser Three Color Immunofluorescence Staining Procedures Based on Energy Transfer Between Phycoerythrin and Cyanine 5," <u>Cytometry</u> , 12(8):723-730 (1991).

TECH CENTER 1600/291

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT		ATTY. DOCKET NO. P-4296P1C1	SERIAL NO. 10/080,868
		APPLICANT Kenneth A. Davis	
		FILING DATE February 22, 2002	GROUP

RECEIVED

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Lavabre-Bertrand, T., "Flow-Cytometric Quantitation in Chronic Leukemias," <u>Histochem.</u> , 40/Suppl.1:33-38 (1996).
	Liu, Z. et al., "Elevated Relative Fluorescence Intensity of CD 38 Antigen Expression on CD 8 ⁺ T Cells is a Marker of Poor Prognosis in HIV Infection: Results of 6 Years of Follow-Up," <u>Cytometry</u> , 26:1-7 (1996).
	Moore, J.P., "Coreceptors: Implications for HIV Pathogenesis and Therapy," <u>Science</u> , 276:51-52 (1997).
	Mujumdar, R.B. et al., "Cyanine Dye Labeling Reagents: Sulfoindocyanine Succinimidyl Esters," <u>Bioconj. Chem.</u> , 4(2):105-111 (1993).
	Mujumdar, R.B. et al., "Cyanine Dye Labeling Reagents Containing Isothiocyanate Groups," <u>Cytometry</u> , 10(1):11-19 (1989).
	Patel, T. et al., "A Fluorometric Assay for Quantitating DNA Strand Breaks During Apoptosis," <u>Anal. Biochem.</u> , 229(2):229-235 (1995).
	Pickar, L.J. et al., "Direct Demonstration of Cytokine Synthesis Heterogeneity Among Human Memory/Effector T Cells by Flow Cytometry," <u>Blood</u> , 86(4):1408-1419 (1995).
	Polk, H.C. et al., "A Systematic Study of Host Defense Processes in Badly Injured Patients," <u>Ann. Surg.</u> , 204(3):282-299 (1986).
	Poncelet, P. et al., "Quantitation of Hemopoietic Cell Antigens in Flow Cytometry," <u>Eur. J. Histochem.</u> , 40/suppl.1:15-32 (1996).
	Rehse, M.A. et al., "Use of Fluorescence Threshold Triggering and High-Speed Flow Cytometry for Rare Event Detection," <u>Cytometry</u> , 22:317-322 (1995).
	Reid, P.A. et al., "Cycling of Cell-Surface MHC Glycoproteins through Primaquine-Sensitive Intracellular Compartments," <u>Nature</u> , 346:655-657 (1990).
	Roche, P.A. et al., "Cell Surface HLA-DR-Invariant Chain Complexes are Targeted to Endosomes by Rapid Internalization," <u>Proc. Natl. Acad. Sci. USA</u> , 90(18):8581-8585 (1993).
	Schneider, Y.-J. et al., "Effect of Chloroquine and Methylamine on Endocytosis of Fluorescein-Labelled Control IgG and of Anti-(Plasma Membrane) IgG by Cultured Fibroblasts," <u>Eur. J. Biochem.</u> , 118(1):33-38 (1981).

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. P-4296P1C1	SERIAL NO. 10/080,868
	APPLICANT Kenneth A. Davis	
	FILING DATE February 22, 2002	GROUP
	RECEIVED JUN 10 2002	



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Schultz, K.R. et al., "The Lysosomotropic Amines, Chloroquine and Hydroxychloroquine: A Potentially Novel Therapy for Graft-Versus-Host Disease," <u>Leukemia and Lymphoma</u> , 24(3/4):201-210 (1997).
	Southwick, P.L. et al., "Cyanine Dye Labeling Reagents-- Carboxymethylindocyanine Succinimidyl Esters," <u>Cytometry</u> , 11(3):418-430 (1990).
	Suni, M.A. et al., "Detection of Antigen-Specific T Cell Cytokine Expression in Whole Blood by Flow Cytometry," <u>J. Immunol. Meth.</u> , 212:89-98 (1998).
	van Vugt, M.J. et al., "Binding of PE-CY5 Conjugates to the Human High-Affinity Receptor for IgG (CD64)," <u>Blood</u> , 88 (6):2358-2360 (1996).
	Volk, H.-D. et al., "Monocyte Deactivation-Rationale for a New Therapeutic Strategy in Sepsis," <u>Inten. Care Med.</u> , 22(4):S474-S481 (1996).
	Volk, H.-D. et al., "Alterations in Function and Phenotype of Monocytes from Patients with Septic Disease - Predictive Value and New Therapeutic Strategies," <u>Behring Inst. Mitt.</u> , (88):208-215 (1991).
	Waggoner, A.S. et al., "PE-CY5, A New Fluorescent Antibody Label for Three-Color Flow Cytometry with a Single Laser," <u>Clinical Flow Cytometry</u> , Annals of the New York Academy of Sciences, A.L. Landy et al., eds., 677:185-193, (1993).
	Watts, C., "Capture and Processing of Exogenous Antigens for Presentation on MHC Molecules," <u>Annu. Rev. Immunol.</u> , 15:821-850 (1997).
	Young, H.A. et al., "Role of Interferon- γ in Immune Cell Regulation," <u>J. Leukocyte Biol.</u> , 58(4):373-381 (1995).
	Zhao, Y.-X. et al., "The Dual Role of Interferon- γ in Experimental <i>Staphylococcus aureus</i> Septicaemia Versus Arthritis," <u>Immunology</u> , 93(1):80-85 (1998).
	Kao, K. J., "Selective elution of HLA antigens and beta 2-microglobulin from human platelets by chloroquine diphosphate," <u>TRANSFUSION</u> , Vol. 28, No. 1, pp. 14-17 (January-February 1988)
	Mane, S. M. et al., "Purification and characterization of human lysosomal membrane glycoproteins," <u>ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS</u> , Vol. 268, No. 1, pp. 360-378 (January 1989)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
P-4296P1C1SERIAL NO.
10/080,868INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Kenneth A. DavisFILING DATE
February 22, 2002

GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Minchinton, R. M. et al., "Evaluation and calibration of a fluorescence-activated cell sorter for the interpretation of the granulocyte immunofluorescence test (GIFT)", <u>CLINICAL AND LABORATORY HAEMATOLOGY</u> , Vol. 11, No. 4, pp. 349-359, (1989)

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
JUN 10 2002
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.